Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

776

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

HPV 16/18 VLP AS04

Trial Locations (27)

15241

GSK Investigational Site, Pittsburgh

19107

GSK Investigational Site, Philadelphia

40004

GSK Investigational Site, Bardstown

40202

GSK Investigational Site, Louisville

54449

GSK Investigational Site, Marshfield

77058

GSK Investigational Site, Houston

84084

GSK Investigational Site, West Jordan

84109

GSK Investigational Site, Salt Lake City

87131

GSK Investigational Site, Albuquerque

94110

GSK Investigational Site, San Francisco

97210

GSK Investigational Site, Portland

98105

GSK Investigational Site, Seattle

94143-0503

GSK Investigational Site, San Francisco

30912-3500

GSK Investigational Site, Augusta

03756

GSK Investigational Site, Lebanon

07960

GSK Investigational Site, Morristown

78205-2489

GSK Investigational Site, San Antonio

80060-900

GSK Investigational Site, Curitiba

90035-903

GSK Investigational Site, Porto Alegre

01409 902

GSK Investigational Site, São Paulo

13083-970

GSK Investigational Site, Campinas

Unknown

GSK Investigational Site, Fortaleza

T6G 2C8

GSK Investigational Site, Edmonton

V3A 4H9

GSK Investigational Site, Langley

R3E 0W3

GSK Investigational Site, Winnipeg

A1E 2C2

GSK Investigational Site, St. John's

M4N 3M5

GSK Investigational Site, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY